Latest News
Corporate News
09.05.2023 | EQS-News
APONTIS PHARMA in Q1 2023 records decline in sales and earnings as expected – 2023 as a transition...
EQS-News: APONTIS PHARMA AG/ Key word(s): Quarterly/ Interim Statement APONTIS PHARMA in Q1 2023 records decline in...
Corporate News
08.05.2023 | EQS-News
APONTIS PHARMA: Keeping up high pace in expansion of Single Pill portfolio - New development...
EQS-News: APONTIS PHARMA AG/ Key word(s): Product Launch APONTIS PHARMA: Keeping up high pace in expansion of Single...
Directors' Dealings
05.05.2023 | EQS-DD
APONTIS PHARMA AG: Silke Reineke, buy
Notification and public disclosure of transactions by persons discharging managerial responsibilities and persons...
Directors' Dealings
05.05.2023 | EQS-DD
APONTIS PHARMA AG: Thomas Milz, buy
Notification and public disclosure of transactions by persons discharging managerial responsibilities and persons...
Ad-hoc News
02.05.2023 | EQS-Ad-hoc
APONTIS PHARMA AG adjusts forecast for fiscal year 2023
APONTIS PHARMA AG/ Key word(s): Forecast/Change in Forecast APONTIS PHARMA AG adjusts forecast for fiscal year 2023...
Corporate News
27.04.2023 | EQS-News
APONTIS PHARMA with first in-licensing of a Single Pill with two active ingredients for the primary...
EQS-News: APONTIS PHARMA AG/ Key word(s): Product Launch APONTIS PHARMA with first in-licensing of a Single Pill...
Corporate News
12.04.2023 | EQS-News
APONTIS PHARMA: New development partnership with Midas Pharma – Expansion of Single Pill portfolio...
EQS-News: APONTIS PHARMA AG/ Key word(s): Product Launch APONTIS PHARMA: New development partnership with Midas...
Corporate News
09.03.2023 | EQS-News
APONTIS PHARMA with successful financial year 2022: Revenue and EBITDA forecast slightly exceeded...
EQS-News: APONTIS PHARMA AG/ Key word(s): Preliminary Results/Annual Results APONTIS PHARMA with successful...